Edition:
United States

Cellectar Biosciences Inc (CLRB.OQ)

CLRB.OQ on NASDAQ Stock Exchange Capital Market

0.75USD
16 Jul 2018
Change (% chg)

-- (--)
Prev Close
$0.75
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
5,492
52-wk High
$20.50
52-wk Low
$5.80

Latest Key Developments (Source: Significant Developments)

Cellectar Announces 1-For-10 Reverse Stock Split
Friday, 13 Jul 2018 04:05pm EDT 

July 13 (Reuters) - Cellectar Biosciences Inc ::CELLECTAR ANNOUNCES 1-FOR-10 REVERSE STOCK SPLIT.CELLECTAR BIOSCIENCES INC - ANNOUNCES A 1-FOR-10 REVERSE SPLIT OF ITS COMMON STOCK, EFFECTIVE AT CLOSE OF BUSINESS TODAY.  Full Article

Cellectar Granted Orphan Drug Designation For CLR 131
Wednesday, 9 May 2018 02:28pm EDT 

May 9 (Reuters) - Cellectar Biosciences Inc ::CELLECTAR GRANTED ORPHAN DRUG DESIGNATION FOR CLR 131 TO TREAT RHABDOMYOSARCOMA.  Full Article

Cellectar Biosciences On Jan 3, Notified Affected Employees Of Its Plan To Reduce Its Workforce By 6 Positions
Monday, 8 Jan 2018 08:57am EST 

Jan 8 (Reuters) - Cellectar Biosciences Inc ::CELLECTAR BIOSCIENCES - ON JAN 3, NOTIFIED AFFECTED EMPLOYEES OF ITS PLAN TO REDUCE ITS WORKFORCE BY 6 POSITIONS -SEC FILING.CELLECTAR BIOSCIENCES-TO RECORD NON-CASH EXPENSES OF ABOUT $1.2 MILLION IN QUARTER ENDED DEC 31 & CASH COSTS OF ABOUT $0.2 MILLION IN 2018, RELATING TO SHUTDOWN.CELLECTAR BIOSCIENCES - IN JAN 2018, CO BEGAN IMPLEMENTING SHUTDOWN OF ITS MANUFACTURING OPERATIONS AT CO'S HEADQUARTERS IN MADISON, WISCONSIN.  Full Article

Cellectar Announces Expansion of Relapsed/Refractory Multiple Myeloma Cohort In Phase 2 Trial of CLR 131
Wednesday, 6 Dec 2017 08:00am EST 

Dec 6 (Reuters) - Cellectar Biosciences Inc ::CELLECTAR ANNOUNCES EXPANSION OF RELAPSED/REFRACTORY MULTIPLE MYELOMA COHORT IN PHASE 2 TRIAL OF CLR 131.CELLECTAR BIOSCIENCES - WILL INCREASE TARGETED PATIENT ENROLLMENT IN R/R MULTIPLE MYELOMA COHORT OF CO'S CURRENTLY ENROLLING CLR 131 PHASE 2 CLINICAL TRIAL.  Full Article

Cellectar Biosciences posts Q3 loss of $0.26 per share
Thursday, 9 Nov 2017 04:01pm EST 

Nov 9 (Reuters) - Cellectar Biosciences Inc :Cellectar Biosciences reports third quarter 2017 financial and corporate performance.Q3 loss per share $0.26.Cash and cash equivalents as of September 30, 2017 were about $5.7 million​.  Full Article

Cellectar updates median overall survival from phase 1 trial in advanced multiple myeloma
Tuesday, 7 Nov 2017 08:30am EST 

Nov 7 (Reuters) - Cellectar Biosciences Inc ::Cellectar announces updated median overall survival of 26.2 months from cohort 1 of clr 131 phase 1 trial in advanced multiple myeloma.  Full Article

Cellectar Biosciences gets additional patent for CLR 131, CLR 125 in Japan
Tuesday, 17 Oct 2017 08:30am EDT 

Oct 17 (Reuters) - Cellectar Biosciences Inc :Cellectar Biosciences receives additional Japanese patent for CLR 131 and CLR 125 for the treatment of various solid tumors.Japanese patent office granted it a patent covering both composition of matter and method of use for CLR 131 and CLR 125​.  Full Article

Cellectar Biosciences and Pierre Fabre extend collaboration
Tuesday, 10 Oct 2017 07:30am EDT 

Oct 10 (Reuters) - Cellectar Biosciences Inc :Cellectar Biosciences and Pierre Fabre extend collaboration for development of new phospholipid drug conjugates.Cellectar Biosciences - ‍aim of extension is to further evaluate synergistic effects observed when Cellectar's phospholipid ethers are combined with Pierre Fabre's novel cytotoxic payloads​.Cellectar Biosciences - ‍program teams will continue to evaluate the new PDC compounds.  Full Article

Cellectar Biosciences says USPTO grants patent for Paclitaxel PDC
Monday, 12 Dec 2016 08:30am EST 

Cellectar Biosciences Inc : Cellectar Biosciences announces USPTO grants patent for Paclitaxel PDC; provides additional patent protection for select solid tumors through 2035 .Cellectar Biosciences - plan to initiate a Phase II trial for CLR 131 in patients with relapsed or refractory multiple myeloma and select hematologic malignancies in early 2017.  Full Article

Cellectar Biosciences files for mixed shelf of upto $10 mln
Friday, 28 Oct 2016 04:50pm EDT 

Cellectar Biosciences Inc - :Files for a mixed shelf of upto $10 million - SEC filing.  Full Article

BRIEF-Cellectar Granted Orphan Drug Designation For CLR 131

* CELLECTAR GRANTED ORPHAN DRUG DESIGNATION FOR CLR 131 TO TREAT RHABDOMYOSARCOMA Source text for Eikon: Further company coverage: